Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia-Reference-Cited by-同舟云学术

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia

Published:2011-05-12 Issue:22 Volume:117 Page:5074-5084
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Guidetti Anna,Carlo-Stella Carmelo,Ruella Marco,Miceli Rosalba,Devizzi Lilli,Locatelli Silvia L.,Giacomini Arianna,Testi Adele,Buttiglieri Stefano,Risso Alessandra,Mariani Luigi,Di Nicola Massimo,Passera Roberto,Tarella Corrado,Gianni Alessandro M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference45 articles.

1. Stem cell transplantation for non-Hodgkin's lymphoma;Wrench;Hematol Oncol Clin North Am.,2008

2. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey;Tarella;J Clin Oncol.,2008

3. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma;Gianni;N Engl J Med.,1997

4. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study;Gordon;Blood.,2004

5. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma;Witzig;J Clin Oncol.,2002

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma;The Oncologist;2024-01-11

2. Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy;JCO Precision Oncology;2022-05

3. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels;Cancers;2021-06-06

4. Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study;Leukemia;2020-03-17

5. Advances in targeted therapy for malignant lymphoma;Signal Transduction and Targeted Therapy;2020-03-06